← All indications
Neuralgia, Postherpetic
Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.
Drugs by status
Approved for this indication (4)
Phase 4 trials (11)
Phase 3 trials (12)
Phase 2 trials (45)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (16)
- Astellas
- Merck
- Analgesic Solutions
- Endo Pharmaceuticals
- Aarhus University
- Korea University
- University of Southern Denmark
- University of Turku
- Zhejiang University
- CHU AMBROISE PARE
- MAC UK Neuroscience Ltd
- Ludwig Maximilians University
- University of Paris
- Technical University of Munich
- European Commission
- University of Helsinki
Organization Involved with Phase 3 Indications (20)
- Daiichi Sankyo
- Eisai
- Takeda
- Grunenthal
- Hepion Pharmaceuticals
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- National Institute of Allergy and Infectious Diseases (NIAID)
- Central South University
- University of Vienna
- Medical University of Vienna
- Janssen Pharmaceutica NV
- University of Sao Paulo
- Bial
- Department of Veteran Affairs
- George Washington University
- CMIC Co, Ltd. Japan
- Wiener Wissenschafts-, Forschungs- und Technologiefonds
- Johnson and Johnson
- Assertio
Organization Involved with Phase 2 Indications (48)
- Zars Pharma Inc.
- Convergence Pharmaceuticals
- Spinifex Pharmaceuticals
- KAI Pharmaceuticals
- XenoPort, Inc.
- Bristol-Myers Squibb
- Bausch Health Companies
- Purdue Pharmaceuticals
- Novartis
- Allergan
- Aestus Therapeutics
- aRigen Pharmaceuticals, Inc.
- Cubist
- INC Research
- Kyowa Hakko Kirin
- Kalypsys, Inc.
- Lexicon Pharmaceuticals
- NeurAxon Inc.
- Samyang Biopharmaceuticals Corporation
- Arvelle
- Sponsor GmbH
- Solvay
- Toray Industries, Inc
- Teva
- Winston Laboratories
- Xenon Pharmaceuticals Inc.
- Daewoong Pharmaceutical Co. LTD.
- Durect
- EpiCept Corporation
- Renovis
- +18 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (19)
- Center for Clinical Studies, Texas
- Harvard University
- Shandong Provincial Hospital
- Shanxi Medical University
- Tanta University
- Capital Medical University
- Peking University
- Zhengzhou University
- Tsinghua University
- Tianjin Medical University
- Cangzhou Central Hospital
- SRL Medisearch
- China Medical University
- Fujian Provincial Hospital
- IQVIA
- Huai'an Second People's Hospital
- Baoding First Center Hospital
- Linfen Fourth People's Hospital
- Lishui Hospital of Traditional Chinese Medicine